Week Ending June 8, 2021

Data reflect disparities in use of next-generation sequencing for lung cancer
“Only one in four Black patients with advanced or metastatic non-small cell lung cancer underwent next-generation sequencing before first-line therapy compared with one in three white patients, according to results of a retrospective study.”

ASCO 2021: Lumakras, First Approved KRAS-targeting Cancer Drug, Looks Promising
“On the heels of last week’s accelerated approval of Lumakras (sotorasib) by the FDA, researchers presented results today from the phase 2 trial that led to drug’s approval at the annual meeting of the American Society of Clinical Oncology.”

New targeted therapy provides survival benefit in KRAS G12C-mutated lung cancer
“Results from the Phase II cohort of the CodeBreaK 100 study showed that treatment with the KRAS G12C inhibitor sotorasib achieved a 37.1% objective response rate and 12.5 months median overall survival in previously treated patients with KRAS G12C-mutated non-small cell lung cancer (NSCLC), according to researchers from The University of Texas MD Anderson Cancer Center. The findings were presented today at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting and published in the New England Journal of Medicine.”

ARROW Trial Update Continues to Support Pralsetinib Use, Biomarker Testing in RET Fusion+ NSCLC
“Durable responses coupled with a tolerable safety profile of pralsetinib (Gavreto) in patients with RET fusion–positive non–small cell lung cancer (NSCLC) was reported from the ARROW trial (NCT03037385) at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, further supporting use of the agent in this patient subset.1”

Better Responses Observed With Selpercatinib Versus Prior Systemic Therapies for RET+ NSCLC
“According to data from the pivotal phase 1/2 LIBRETTO-001 trial (NCT03157128) of selpercatinib (Retevmo) in patients with RET fusion–positive non–small cell lung cancer (NSCLC), the kinase inhibitor was able to induce consistent antitumor benefit regardless of treatment in prior lines of therapy.1”

Nucleix, MD Anderson Partner on Methylation-Based Lung Cancer Dx Tests
“NEW YORK – Israeli molecular diagnostics firm Nucleix said on Thursday that it has signed a research and license agreement with the University of Texas MD Anderson Cancer Center to evaluate and develop methylation assays focusing on lung cancer.”

Lung Cancer Research Foundation and EGFR Resisters Announce Partnership
“Groups join forces to fund mutation-specific research
NEW YORK, June 3, 2021 /PRNewswire/ — The Lung Cancer Research Foundation (LCRF) is excited to announce a partnership with leading lung cancer patient advocacy group, the EGFR Resisters. This multi-year partnership will kick off on June 6th, National Cancer Survivor’s Day, in a joint effort in 2021 to fund an LCRF Pilot Grant related to EGFR positive lung cancer.”

Atezolizumab Extends Disease-Free Survival in Patients with PD-L1 Positive Early NSCLC
“Pharmaceutical maker Roche says its monoclonal antibody (atezolizumab) Tencentriq has been shown to be successful at reducing the risk of recurrence or death in a subset of patients with non-small-cell lung cancer (NSCLC) whose tumors express at least 1% programmed death-ligand 1 (PD-L1).”